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Should cost effectiveness analyses for NICE always
consider future unrelated medical costs?
More health would result from including all future care costs in decisions to approve interventions,
write Pieter van Baal and colleagues. Sarah Davis worries that always including unrelated costs
might lead to unfair distribution of care, including among people with incurable illness
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When developing guidance on the use of new technologies in
the NHS, the National Institute for Health and Care Excellence
(NICE) recommends considering their cost effectiveness. NICE
deems an intervention cost effective if its “health benefits are
greater than the opportunity costs of programmes displaced to
fund the new technology, in the context of a fixed NHS budget.
In other words, the general consequences for the wider group
of patients in the NHS are considered alongside the effects for
those patients who may directly benefit from the technology.”1
Currently, NICE explicitly states that future medical costs
incurred that are not directly related to the intervention in
question should be excluded from economic analyses. But NICE
should change its definition to include consideration of these
costs.2
What are unrelated medical costs?
Medical interventions that prolong a patient’s life often create
additional consumption of medical goods and services in years
that would not have been lived without the intervention. Some
of this consumption is directly related to the intervention. For
example, after a successful heart transplantation, the costs of
visiting the cardiologist in the years gained are considered to
be related. These costs are typically included in economic
analyses. But other medical costs in added years are not directly
related to the intervention. The costs of dementia care in added
years after the same heart transplantation would be an example
of such future unrelated costs.
Dutch guidelines have been revised and now advise inclusion.3
New US guidance also recommends inclusion of future unrelated
medical costs in economic analyses.4 These changes are in line
with economic theory5 6 that shows that including costs of
unrelated diseases in cost effectiveness analyses would result
in more efficient allocation of resources that would increase
population health. Estimating such costs is not difficult given
current knowledge on how ageing affects healthcare use.7 8
Different choices, more health
It may seem counterintuitive that including more costs in
economic evaluations, making interventions seem more
expensive, ultimately results in more health. However, given a
fixed budget, including all future costs, leads to different choices
that, on balance, result in more health.5
If unrelated future costs are neglected, life prolonging
technologies seem more cost effective than they truly are.
Ultimately, these future unrelated costs will have to be paid and
this will reduce the budget left for other care. Given that NHS
budgets are fixed, the opportunity costs of implementing new
technologies consist of quality adjusted life years (QALYs)
forgone because of disinvestment in technologies for
unidentified patients in the future. Ignoring future unrelated
medical costs results in an underestimate of losses in QALYs
for these patients. Intuitively, including the costs of unrelated
medical care also makes sense because unrelated care also
contributes to health gains, which are currently implicitly
included in assessments of health benefits.5 6
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For technologies that substantially extend life, including future
unrelated medical costs may substantially affect cost
effectiveness, potentially triggering difficult ethical debates.9 10
Denying any patient a treatment because of cost can be ethically
troubling. However, opportunity cost is not only an economic
concept but also an ethical one, because of health losses among
other patients. The relevant policy question is whether we are
willing to sacrifice health gains in these other patient groups
(which may be higher) to yield health gains in a specific patient
group. Pretending that future unrelated medical costs do not
exist is equivalent to deeming the lives of some future patients
worthless, which is neither fair nor ethically acceptable.
Ethical dilemmas should be dealt with explicitly in fully
informed decision processes. NICE emphasises that decisions
should be made through fair procedures that allow for ethical
arguments to be considered.10 Analysts should provide decision
makers with a full picture of the consequences for the healthcare
budget, now and in the future; to do otherwise is inconsistent
with NICE’s definition of cost effectiveness. Only then can
those with the responsibility for decision making come to an
informed judgment considering the relevant (ethical) trade-offs.
No—Sarah Davis
The objective of welfare economics is to maximise population
health from a fixed healthcare budget. To achieve this objective,
economic evaluations of different healthcare interventions
should consider all consequences related to healthcare, including
future medical costs unrelated to the interventions.5
The problem comes when trying to implement this approach in
the real world. The utilitarian objective of maximising
population health does not take into account whether health
gains within the population are distributed fairly.
In some situations, inclusion of unrelated costs would preclude
specific groups of people from having equitable access to care.
In these cases, decision makers should consider cost
effectiveness analyses that exclude unrelated costs.
A patient receiving dialysis
The classic example cited to justify the exclusion of unrelated
costs is that of a life extending treatment in a patient receiving
dialysis where the treatment does not alter the need for lifelong
dialysis.9 If dialysis is expensive, and the quality of life of
patients receiving dialysis is low, then the value of the life years
gained by the treatment may not outweigh the cost of dialysis
during those additional life years. In this situation, the life
extending treatment would not be cost effective even if it were
provided at zero cost.11
Some health economists have argued that if the treatment being
evaluated does not alter the need for lifelong dialysis, then the
dialysis costs can be considered to be unrelated because the
increased cost is driven solely by the increased longevity of the
patient.9 The exclusion of future dialysis costs on this basis
allows cost effective prices to be identified for life extending
treatments in this patient group.
This situation may apply among any group of patients with high
ongoing costs that cannot be reduced by better care. In the UK
this may include people with high social care needs because of
disability, because NICE requires costs met by personal and
social services to be included in cost effectiveness analyses.1
As a society we would never refuse to provide good preventive
healthcare, such as flu vaccinations, to patients with disabilities
purely because their high ongoing health and social care costs
would mean that their early death would release funds that would
generate more health gains elsewhere in the health system. A
decision to do so would be unethical and would face legal
challenges under the UK’s equalities legislation.12
This same ethical argument can apply when considering
interventions that are indicated only for groups of patients who
need expensive ongoing care. It would be inequitable to fund
technologies that are not themselves cost effective but to refuse
to fund life extending treatments in populations receiving those
cost ineffective technologies. The effect of such a decision
would be to deny patients more of a treatment already
prolonging their life when new patients would be able to receive
it.11
Healthcare systems have more than one
purpose
Some health economists might argue that more health would
be gained by society as a whole if funding was removed from
cost ineffective interventions and spent on cost effective
interventions elsewhere in the healthcare system. However, the
point here is that healthcare systems are not currently configured
to maximise population health because that is not their only
purpose.
Society also values providing compassionate care to patients
who cannot currently be cured, with the aim of maximising the
health that can be achieved during their individual lifetimes. If
the societal value of providing such care is not currently captured
in cost effectiveness analyses, then excluding these costs as
unrelated may be a means to appraise technologies in these
populations in an equitable manner. It is for these reasons that
NICE asks that unrelated future medical costs are omitted from
cost effectiveness analyses.
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